Dear readers of, please forgive the disruption. needs about $36850 in 2023. In 2022 we received donations from third parties of about $ 13870. Unfortunately, 99.8% of our readers do not donate. If everyone who reads this request makes a small contribution, our fundraising campaign for 2023 would be over after a few days. This donation request is displayed 18,000 times a week, but only 40 people donate. If you find useful, please take a minute and support with your donation. Thank you!

Since 01.06.2021 is supported by the non-profit ADxS e.V..

$27450 of $36850 - as of 2023-11-30
Header Image
Modafinil for ADHD


Modafinil for ADHD

Modafinil is a stimulant that has no longer been subject to narcotics law since 2008 and has also been available as a generic since 2012. The molecular structure differs significantly from amphetamines.

Trade names: Provigil (USA), Generic

The regular use is narcolepsy. It is used off-label for ADHD. In ADHD with comorbid narcolepsy, it is likely to be the drug of first choice.

Even as a generic, modafinil is still disproportionately expensive. Off-label use outside the approved indication narcolepsy is therefore unlikely to be covered by health insurers.

1. Modafinil for ADHD (off label)

Because modafinil has been associated with the occurrence of Stevens-Johnsons syndrome, modafinil is not approved for the treatment of ADHD and therefore can only be used off-label.1

There are quite a few reports from ADHD sufferers in forums about a very positive effect of Modafinil, as well as reports from non-responders. Modafinil has a very consistent effect throughout the day with a half-life of 12 to 15 hours and in this respect is superior to most MPH products or amphetamine salts.

Several larger double-blind placebo-controlled studies confirm modafinil has good efficacy in ADHD.234

A study in adults came to the divergent conclusion of good tolerability, but found no significant improvements in ADHD symptoms over placebo.5

Modafinil has an effect size of 0.65 in ADHD for both ADHD-I and ADHD-C.6 This corresponds to the value of atomoxetine (Strattera).
Efficacy of different forms of treatment for ADHD

2. Modafinil pathways of action

The mode of action of modafinil is not yet fully understood. There seems to be a strong dopaminergic component.7

Modafinil apparently increases orexin levels. This could be one of the pathways of action of modafinil in the treatment of narcolepsy.8

In ADHD-I, orexin levels appear to be decreased. See more at Orexin/hypocretin In this regard, modafinil might find a specific application in ADHD-I.

3. Modafinil side effects

One of the side effects of modafinil is that modafinil increases histamine,9 as do the well-known ADHD medications:

  • Amphetamine drugs
  • Methylphenidate
  • Atomoxetine
  • Nicotine
  • Caffeine

Therefore, people with histamine intolerance often have problems by taking ADHD medications.
One ADHD sufferer with histamine intolerance reported that she could not tolerate AMP and sustained-release MPH at all, but could tolerate sustained-release MPH in small doses.

  1. Walitza, Romanos, Renner, Gerlach (2016): Psychostimulanzien und andere Arzneistoffe, die zur Behandlung der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) angewendet werden, S. 291, in; Gerlach, Mehler-Wex, Walitza, Warnke (Hrsg,) (2016): Neuro-/Psychopharmaka im Kindes- und Jugendalter: Grundlagen und Therapie.

  2. Biederman, Pliszka (2008): Modafinil Improves Symptoms of Attention-Deficit/Hyperactivity Disorder across Subtypes in Children and Adolescents; The Journal of Pediatrics, March 2008, Volume 152 , Issue 3 , 394 – 399.e2, n = 638

  3. Swanson, Greenhill, Lopez, Sedillo, Earl, Jiang, Biederman (2006): Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. J Clin Psychiatry. 2006 Jan;67(1):137-47.

  4. Wang, Han, Lee, Jun, Patkar, Masand, Pae (2017): Modafinil for the treatment of attention-deficit/hyperactivity disorder: A meta-analysis. J Psychiatr Res. 2017 Jan;84:292-300. doi: 10.1016/j.jpsychires.2016.09.034.

  5. Arnold, Feifel, Earl, Yang, Adler (2014): A 9-week, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate the efficacy and safety of modafinil as treatment for adults with ADHD. J Atten Disord. 2014 Feb;18(2):133-44. doi: 10.1177/1087054712441969. n = 330

  6. Metaanalyse einer hohen Anzahl von Studien durch Taylor (Eric), European guidelines on diagnosis and treatment of ADHD, Vortrag auf dem internationalen Symposium in Achen, 14.03.2007, zitiert nach Kühle, Dr. med Hans-Jürgen, Neurofeedbacktherapie bei ADHS, Giessen 2010 (PDF von Webseite Dr. Kühle, Download Februar 2018), Kapitel 7

  7. Quisenberry, Baker (2015): Dopaminergic mediation of the discriminative stimulus functions of modafinil in rats. Psychopharmacology (Berl). 2015 Dec;232(24):4411-9. doi: 10.1007/s00213-015-4065-0.

  8. Willie, Renthal, Chemelli, Miller, Scammell, Yanagisawa, Sinton (2005): Modafinil more effectively induces wakefulness in orexin-null mice than in wild-type littermates. Neuroscience. 2005;130(4):983-95.

  9. Ishizuka, Sakamoto, Sakurai, Yamatodani (2003): Modafinil increases histamine release in the anterior hypothalamus of rats. Neurosci Lett. 2003 Mar 20;339(2):143-6. doi: 10.1016/s0304-3940(03)00006-5. PMID: 12614915.